Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.

Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N, Herrlinger U, Tabatabai G.

Neuro Oncol. 2019 Apr 23. pii: noz071. doi: 10.1093/neuonc/noz071. [Epub ahead of print] No abstract available.

PMID:
31089718
2.

Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.

Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T, Suenaga M, Sato H, Sugiyama E, Yamaguchi K, Hama T.

Oncology. 2019;96(4):200-206. doi: 10.1159/000495989. Epub 2019 Feb 14.

PMID:
30763946
3.

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.

Belum VR, Wu S, Lacouture ME.

Invest New Drugs. 2013 Aug;31(4):1078-86. doi: 10.1007/s10637-013-9977-0. Epub 2013 May 23.

PMID:
23700287
4.

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.

Yin X, Yin Y, Shen C, Chen H, Wang J, Cai Z, Chen Z, Zhang B.

Onco Targets Ther. 2018 Oct 2;11:6405-6414. doi: 10.2147/OTT.S156760. eCollection 2018.

5.

A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.

Melosky BL, Lim HJ, Davies JM, Gill S, Kollmannsberger CK, Ho MY, Vandt SA, Renouf DJ.

Cancer Chemother Pharmacol. 2019 Mar;83(3):411-417. doi: 10.1007/s00280-018-3738-x. Epub 2018 Dec 8.

6.

Regorafenib in patients with recurrent high-grade astrocytoma.

Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.

PMID:
30820715
7.

Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.

Nonomiya Y, Yokokawa T, Kawakami K, Kobayashi K, Aoyama T, Takiguchi T, Sugisaki T, Suzuki K, Suenaga M, Wakatsuki T, Yamaguchi K, Sugimoto Y, Hama T.

Oncol Res. 2019 May 7;27(5):551-556. doi: 10.3727/096504018X15291727589740. Epub 2018 Jun 18.

PMID:
29914591
8.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK.

Cancer Res Treat. 2017 Apr;49(2):350-357. doi: 10.4143/crt.2016.067. Epub 2016 Jul 19.

9.

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.

10.

Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.

Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, Perrin C, Delcambre C, Liegl-Atzwanger B, Toulmonde M, Dumont S, Ray-Coquard I, Clisant S, Taieb S, Guillemet C, Rios M, Collard O, Bozec L, Cupissol D, Saada-Bouzid E, Lemaignan C, Eisterer W, Isambert N, Chaigneau L, Cesne AL, Penel N.

Lancet Oncol. 2016 Dec;17(12):1732-1742. doi: 10.1016/S1470-2045(16)30507-1. Epub 2016 Oct 14.

PMID:
27751846
11.

Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.

Fukuoka S, Shitara K, Noguchi M, Kawazoe A, Kuboki Y, Bando H, Okamoto W, Kojima T, Doi T, Ohtsu A, Yoshino T.

Clin Colorectal Cancer. 2017 Jun;16(2):e39-e44. doi: 10.1016/j.clcc.2016.07.012. Epub 2016 Aug 18.

PMID:
27780748
12.

Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.

Kim K, Jha R, Prins PA, Wang H, Chacha M, Hartley ML, He AR.

Cancer Chemother Pharmacol. 2017 Nov;80(5):945-954. doi: 10.1007/s00280-017-3431-5. Epub 2017 Sep 20.

PMID:
28932966
13.

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ.

Clin Colorectal Cancer. 2018 Jun;17(2):e395-e414. doi: 10.1016/j.clcc.2018.02.010. Epub 2018 Feb 27.

PMID:
29606345
14.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.

Zhang Z, Jiang T, Wang W, Piao D.

Medicine (Baltimore). 2017 Dec;96(48):e8698. doi: 10.1097/MD.0000000000008698.

15.

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.

Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T.

Int J Clin Oncol. 2015 Oct;20(5):905-12. doi: 10.1007/s10147-015-0790-y. Epub 2015 Feb 6.

16.

A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.

Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee JJ, Bahary N, Chu E, Streeter N, Drummond S.

Cancer. 2019 Mar 15;125(6):902-909. doi: 10.1002/cncr.31872. Epub 2018 Dec 18.

PMID:
30561756
17.

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.

Calcagno F, Lenoble S, Lakkis Z, Nguyen T, Limat S, Borg C, Jary M, Kim S, Nerich V.

Clin Med Insights Oncol. 2016 Jul 4;10:59-66. doi: 10.4137/CMO.S38335. eCollection 2016.

18.

Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.

Shirley M, Keating GM.

Drugs. 2015 Jun;75(9):1009-17. doi: 10.1007/s40265-015-0406-x. Review.

PMID:
25998375
19.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group.

Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23.

PMID:
30477937
20.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

Supplemental Content

Support Center